FDA Approves NGENLA — Pfizer Laboratories Div Pfizer Inc

# FDA Approves Pfizer's NGENLA (somatrogon-ghla) for Growth Hormone Deficiency Pfizer has received FDA approval for NGENLA (somatrogon-ghla), a long-acting growth hormone therapy administered via subcutaneous injection, positioning the company to capture market share in the human growth hormone replacement market currently dominated by frequent-dosing competitors. The approval of this once-weekly treatment option could drive significant adoption among patients seeking improved convenience and compliance, while potentially pressuring sales of traditional daily or multi-weekly growth hormone products.